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Background: HDL carries a rich protein cargo and examining HDL protein composition promises to improve our
understanding of its functions. Conventional mass spectrometry methods can be lengthy and difficult to extend to
large populations. In addition, without prior enrichment of the sample, the ability of these methods to detect low
abundance proteins is limited. Our objective was to develop a high-throughput approach to examine HDL protein
composition applicable to diabetes and cardiovascular disease (CVD).
Methods: We optimized two multiplexed assays to examine HDL proteins using a quantitative immunoassay
(Multi-Analyte Profiling- MAP) and mass spectrometric-based quantitative proteomics (Multiple Reaction
Monitoring-MRM). We screened HDL proteins using human xMAP (90 protein panel) and MRM (56 protein panel).
We extended the application of these two methods to HDL isolated from a group of participants with diabetes and
prior cardiovascular events and a group of non-diabetic controls.
Results: We were able to quantitate 69 HDL proteins using MAP and 32 proteins using MRM. For several common
proteins, the use of MRM and MAP was highly correlated (p < 0.01). Using MAP, several low abundance proteins
implicated in atherosclerosis and inflammation were found on HDL. On the other hand, MRM allowed the
examination of several HDL proteins not available by MAP.
Conclusions: MAP and MRM offer a sensitive and high-throughput approach to examine changes in HDL proteins
in diabetes and CVD. This approach can be used to measure the presented HDL proteins in large clinical studies.
Keywords: High density lipoprotein, Proteomics, Multiple reaction monitoring, Multi-analyte panel, Diabetes,
Cardiovascular diseaseIntroduction
Recent findings suggest that HDL carries over 80 proteins
involved in lipid metabolism, complement regulation,
acute phase response and proteinase inhibition [1]. This
protein cargo appears to be remodeled in metabolic syn-
drome [2], cardiovascular disease [1,3] and after choles-
terol therapies [4]. However, measurement of proteins
associated with lipids and that span several orders of mag-
nitude in abundance can be challenging. Conventional
LC-MS/MS assays and label-free quantitation methods
using spectral counting or extracted ion chromatograms
(XIC) used in the previous studies [1-4] can be lengthy* Correspondence: hyassine@usc.edu
1Department of Medicine, University of Southern California, Los Angeles, CA,
USA
Full list of author information is available at the end of the article
© 2014 Yassine et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.and are limited to small sample sizes. Multiple Reaction
Monitoring (MRM), on the other hand, is a tandem MS
(MS/MS) scan mode unique to triple quadrupole MS
instrumentation that is capable of rapid, sensitive, and
specific quantitation of peptides in highly complex sample
matrices, such as plasma [5,6]. MRM is a targeted
approach that requires knowledge of the molecular
weight the peptide of interest and its fragmentation pat-
tern, leading to the generation of target “transitions” for
monitoring protein levels. When coupled with stable
isotope peptide standards (SIS peptides), quantitation
using MRM can be highly reproducible [7]. MRM quanti-
tation has been successfully applied to plasma proteins
[5,6] and, more recently, to a limited subset of HDL
proteins [8]. Without pre analytical depletion or enrich-
ment, MRM sensitivity can be compromised by theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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sensitivity of MRM allows analyses at levels down to
one ng/mL, the accuracy at the lower end of the abun-
dance range can be problematic. In this case, the use of
methods that deplete the higher abundance proteins is
often needed. These methods, however, can lead to the
unintentional removal of proteins that are attached to
the depleted proteins. An alternative approach is the
use of immunoassays that offer much improved sensitivity.
One example of these assays is multiplexed immunoassay
panels (MAP). MAP compliments MRM at this low end
and helps ensure that proteins are fully and correctly
quantitated at the low range.
There has been considerable interest in understanding
HDL functions in light of the strong inverse association
of HDL cholesterol and cardiovascular disease (CVD)
and the lack of improved CVD outcomes after raising
HDL’s cholesterol content in three recent trials [9-11].
Knowledge of HDL protein composition promises to
improve our understanding of HDL’s multiple functions
in CVD. In this study, we optimized two approaches to
measure HDL proteins using multiplexed immunoassays
(Multi-Analyte Profiling-MAP) and quantitative proteo-
mics (MRM) platforms. We extended the application of
these two techniques to HDL isolated from participants
with and without diabetes and CVD. Our findings suggest
that MAP can be used to monitor low abundance proteins
on HDL, whereas MRM allows examining higher abun-
dance HDL proteins without the need for pre-existing
antibodies.Materials and methods
Clinical samples
The study was approved by the University of Arizona
Institutional Review Board, and all patients provided
written informed consent prior to testing. The samples
were collected at University of Arizona Medicine Clinics.
Participants reported to the Center for Clinical and
Translational Sciences (CaTS) after an overnight fast.
Samples were collected in EDTA containing tubes. The
presence of cardiovascular disease was defined by a
prior history of coronary artery bypass surgery (CABG),
percutaneous transluminal angioplasty (PTCA), prior
MI, or thrombotic stroke. Patients were older than 18
years of age. New diagnosis of diabetes was based on 2
hour oral glucose tolerance test (OGTT) > 200 mg/dl or
glycated hemoglobin (HbA1c > 6.5%). Established diabetes
was defined by clinical history. The study included disease
free participants and participants with advanced kidney
disease, diabetes and CVD. The study excluded subjects if
they met any of the following criteria: had type had 1
diabetes, were on an active weight loss program, history
of cancer, HIV, or steroid use.HDL Isolation technique
HDL isolation by centrifugation was based on a modifi-
cation of a previously published protocol [1]. In brief,
potassium bromide (KBr ~55 mg) was added to 310 μl
of plasma samples to create a density of 1.21 g/mL. The
sample was overlaid with 200 μL of 1.21 g/mL density
solution for a total volume was 500 μL. Samples were
then spun at 120,000 rpm, at 16°C for 2 hours (Beckman
TLX ultracentrifuge with a type 120.1 fixed angle rotor
using thick-walled 500 μL Polycarbonate tubes, item
343776). The upper 125 μL solution that had a density
of less than 1.21 g/mL was removed and 150 μL of
NaCl/EDTA solution (0.9% (w/v) NaCl, 0.1% (w/v) EDTA,
pH 7.4) was added to each tube for a final density of
1.063 g/mL. Subsequently, 225 μL of 1.06 KBr solutions in
NaCl/EDTA was underlaid with a final volume of 500 μL
for a second 2 hour spin at the same parameters listed.
The bottom 125 μL (HDL fraction) of solution was re-
moved for further analysis. Four HDL samples were sent
to Myriad RBM to externally validate our measurements
using an immunoassay in a CLIA certified laboratory. To
confirm depletion of albumin and apoB proteins from
HDL samples, HDL from a CVD pool was isolated with a
second approach that involved long centrifugations at two
sequential spins each of 10 hours duration using the above
technique. Albumin levels were then measured using a
commercial ELISA (Assaypro).
Measurements of HDL proteins
We screened HDL using the human MAP panel (90 pro-
teins) and MRM panel (56 proteins). The proteins that were
detected on HDL are summarized in Table 1. Four HDL
samples were used to compare protein measures by MAP
and MRM. Subsequently, two pools of HDL samples (each
pool 500 μL combined from 10 HDL isolates) - one pooled
from ten non-diabetic subjects defined as the control group
and a second pooled from ten subjects with both diabetes
and CVD–defined as the disease group were run on the
MAP platform using the HumanMAP panel and by MRM.
MAP
The samples were analyzed at Myriad RBM that uses
Luminex xMAP. Luminex xMAP is a well-established
particle array system that is based on beads with unique
fluorescent signatures with proprietary multi-analyte panel
targets assessed for cross-reactivity. This technology has
been used for the detection of numerous targets, such as
cytokines [12], cancer markers [13], and indicators for
various disease states [14]. The assay details of this plat-
form are well described in Myriad RBM website (www.
myriadrbm.com). Here we applied MAP to HDL samples
obtained by ultracentrifugation in both 2X2 and 10X10
isolation techniques, calculating the limit of detection and
the recovery analysis after 12 dilutions. The data is
Table 1 Proteins that were quantified on HDL from the healthy and diseased sample pool
MAP (69 proteins quantified out of 90) MRM (32 proteins quantified out of 56)
Protein Uniprot ID ID Uniprot ID
C-Reactive Protein (CRP) P02741 Apolipoprotein D P05090
von Willebrand Factor (vWF) P04275 Apolipoprotein A-I P02647
Adiponectin Q15848 Apolipoprotein A-II precursor P02652
Fibrinogen P02671, P02675, P02679 Apolipoprotein A-IV P06727
Serum Amyloid P-Component (SAP) P02743 Apolipoprotein B-100 P04114
Sex Hormone-Binding Globulin (SHBG) P04278 Apolipoprotein C-I lipoprotein P02654
Immunoglobulin A (IgA) P44969 Apolipoprotein C-III P02656
Complement C3 (C3) P01024 Apolipoprotein E P02649
Protein S P26447, P06703 Apolipoprotein L1 O14791
Thrombospondin-1 P07996 Beta-2-glycoprotein I_Apo H P02749
Haptoglobin P00738 Apolipoprotein C-II P02655
Complement factor H P08603 Apolipoprotein(a) P08519
Ferritin (FRTN) P02794, P02792 Apolipoprotein M O95445
Alpha-2-Macroglobulin (A2Macro) P01023 PON 1 P27169
Myeloperoxidase (MPO) P05164 Albumin P02768
Plasminogen Activator Inhibitor 1 (PAI-1) P05121 Alpha-1-Anti-trypsin P01009
Tumor Necrosis Factor Receptor 2 (TNFR2) P20333 Alpha-1B-glycoprotein P04217
Insulin P01308 Alpha-2-antiplasmin P08697
Vitronectin P04004 Alpha-2-HS-glycoprotein P02765
Calcitonin P01258 Clusterin P10909
Beta-2-Microglobulin (B2M) P61769 Complement C1 inactivator P05155
CD5L O43866 Complement C3 P01024
Intercellular Adhesion Molecule 1 (ICAM-1) P05362 Complement C4 beta chain P0C0L5
CD 40 antigen (CD40) Q6P2H9 Complement C4 gamma chain P0C0L5
Carcinoembryonic Antigen (CEA) P06731 Complement C9 P02748
Vascular Endothelial Growth Factor (VEGF) P15692 Complement factor H P08603
Thyroxine-Binding Globulin (TBG) P05543 Fibrinogen alpha chain P02671
Vascular Cell Adhesion Molecule-1 (VCAM-1) P19320 Fibrinogen beta chain P02675
Thyroid-Stimulating Hormone (TSH) P01215, P01222 Fibrinogen gamma chain P02679
Brain-Derived Neurotrophic Factor (BDNF) P23560 Fibrinopeptide A P02671
Matrix Metalloproteinase-3 (MMP-3) P08254 Haptoglobin beta chain P00738
Fatty Acid-Binding Protein, heart (FABP, heart) P05413 Hemopexin P02790
Tissue Inhibitor of Metalloproteinases 1 (TIMP-1) P01033 Heparin cofactor II P05546
Myoglobin P02144 Kininogen-1 P01042
Immunoglobulin M (IGM) P01871 L-selectin P14151
Interleukin-8 (IL-8) P10145
Interleukin-1 beta (IL-1 beta) P01584
EN-RAGE P80511
Interleukin-1 alpha (IL-1 alpha) P01583
Monocyte Chemotactic Protein 1 (MCP-1) P13500
Macrophage Inflammatory Protein-1 beta (MIP-1 beta) P13236
Alpha-1-Antitrypsin (AAT) P01009
Fetuin A (alpha HS-glycoprotein) P02765
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Table 1 Proteins that were quantified on HDL from the healthy and diseased sample pool (Continued)
Interleukin-15 (IL-15) P40933
Epidermal Growth Factor (EGF) P01133
Apolipoprotein D (Apo D) P05090
Eotaxin-1 P51671
Apolipoprotein(a) (Lp(a)) P08519
Macrophage-Derived Chemokine (MDC) O00626
Clusterin (CLU) P10909
Prostate-Specific Antigen, Free (PSA-f) P07288
Apolipoprotein A-I (Apo A-I) P02647
Leptin P41159
Matrix Metalloproteinase-9 (MMP-9) P14780
Interleukin-10 (IL-10) P22301
Interleukin-18 (IL-18) Q14116
Interleukin-2 (IL-2) P60568
Lymphotactin P47992
T-Cell-Specific Protein RANTES (RANTES) P13501
Erythropoietin (EPO) P01588
Serum Glutamic Oxaloacetic Transaminase (SGOT) P17174
Apolipoprotein E (Apo E) P02649
Epithelial-Derived Neutrophil-Activating Protein 78 (ENA-78) P42830
Stem Cell Factor (SCF) P21583
Interleukin-13 (IL-13) P35225
Apolipoprotein B (Apo B) P04114
Growth Hormone (GH) P01241
Interleukin-4 (IL-4) P05112
Interleukin-1 receptor antagonist (IL-1ra) P18510
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applied to the control and disease HDL sample pool.
MRM
The samples were analyzed at the University of Victoria -
Genome BC Proteomics Centre with a dedicated core ser-
vice for MRMs with the capacity of high throughput stable
isotope peptide production for absolute quantification.
We screened HDL protein using existing published
transitions that were previously applied to plasma pro-
teins [6] or to newly developed transitions from pro-
teins that are associated with HDL (LCAT, CETP,
PLTP, PON1, Apolipoprotein D, Apolipoprotein M,
Apolipoprotein L1, Apolipoprotein CII) or of interest
to CVD (Macrophage migration inhibitory factor,
Matrix Gla protein). The transition list used is pro-
vided in Additional file 1: Table S2. For the generation
of CV data, the samples were injected four times per
method, with two methods in total. The total number
of transitions per sample was 142 (method 1-lowabundant specific targets) + 88 (method 2-general high
abundance plasma protein targets). There were between
1–5 transitions monitored for each peptide. Proteins
with new transitions, or those that were low in abun-
dance were monitored using either multiple peptides
(as CETP, MIF, PON1) or up to 5 transitions per pep-
tide. The methods were not scheduled as the retention
times shifted between HDL isolation procedures that
can result in non-quantifiable data. Based on these rep-
licate runs, we selected one transition for quantitation
analysis based on the lowest coefficient of variation by
the 4 replicate “technical” runs. These transitions are
summarized in Table 2. The selection process of these
transitions (to exclude interferences or amino acid modifi-
cations such as phosphorylation and glycosylation) was
previously described [6,15] in detail and included in
the (Additional file 1: MRM methods). Representative
chromatograms of the healthy pool HDL transitions
and disease pool HDL transitions are also included in
the figure Additional file 1: Figure S1.
Table 2 HDL peptides selected for MRM
Mass info (Q1/Q3) Protein Peptide sequence Fragment ion %CV (n = 8)
575.3/937.5 Albumin LVNEVTEFAK y8 5.3
555.8/797.4 Alpha-1-Anti-trypsin LSITGTYDLK y7 23.9
656.8/771.4 Alpha-2-antiplasmin LGNQEPGGQTALK y8 116.2
399.5/490.3 Alpha-2-HS-glycoprotein HTLNQIDEVK y4 33.6
437.2/540.3 Antithrombin-III DDLYVSDAFHK y++9 63.2
409.3/599.4 Apolipoprotein M AFLLTPR y5 6.4
405.9/572.8 Apolipoprotein A-I ATEHLSTLSEK y10++ 1.2
486.8/443.2 Apolipoprotein A-II precursor SPELQAEAK y++8 4.5
524.3/450.8 Apolipoprotein B-100 FPEVDVLTK y++8 20.7
516.8/466.2 Apolipoprotein C-I lipoprotein TPDVSSALDK y++9 5.4
519.3/666.3 Apolipoprotein C-II TAAQNLYEK y5 3.4
598.8/244.1 Apolipoprotein C-III GWVTDGFSSLK b2 14.2
436.3/659.3 Apolipoprotein D VLNQELR y5 6.5
484.8/588.3 Apolipoprotein E LGPLVEQGR y5 2.1
815.9/651.3 Apolipoprotein L1 VTEPISAESGEQVER y++12 26.7
786.5/535.3 Apolipoprotein (a) LFLEPTQADIALLK y++10 45.1
511.8/751.4 Beta-2-glycoprotein I_Apo H ATVVYQGER y6 42.6
644.8/602.3 Clusterin ELDESLQVAER y5 45.6
501.8/731.4 Complement C3 TGLQEVEVK y6 50.8
557.8/629.4 Complement C4 beta chain VDGTLNLNLR y5 89.9
362.9/487.3 Complement C4 gamma chain ITQVLHFTK y++8 16.1
508.6/494.3 Complement C9 TEHYEEQIEAFK y4 44.3
671.4/830.4 Complement factor H SPDVINGSPISQK y8 63.0
570.8/867.5 Fibrinogen alpha chain GSESGIFTNTK y8 50.1
497.9/600.3 Fibrinogen gamma chain YEASILTHDSSIR y++11 17.3
768.8/1077.5 Fibrinopeptide A ADSGEGDFLAEGGGVR y11 95.1
490.8/562.3 Haptoglobin beta chain VGYVSGWGR y5 59.9
610.8/480.3 Hemopexin NFPSPVDAAFR y++9 147.9
514.8/814.4 Heparin cofactor II TLEAQLTPR y7 31.9
626.3/1051.5 Kininogen-1 TVGSDTFYSFK y9 28.9
497.8/794.4 L-selectin AEIEYLEK y6 64.4
592.8/943.5 PON 1 IQNILTEEPK y8 51.0
HDL proteins that were quantified using MRM. The CV was calculated using 4 technical runs.
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We used the statistical program R2.1 (R core develop-
ment team). The characteristics of the two pools were
compared using an independent sample test or a propor-
tion test. The correlation coefficient and the p value gen-
erated between plasma proteins and HDL proteins was
obtained using spearman correlation test.
Results and discussion
Description of study participants
The goal of this project was to use sensitive and high
throughout approach to analyze HDL proteins in healthand vascular disease such as diabetes and CVD. The
samples were selected to detect differences in HDL pro-
teins between healthy controls and patients with
chronic vascular disease. The study demographics and
biochemical measurements are listed in Table 3. The
two groups were age and sex matched. All diseased indi-
viduals had a history of CVD events prior to participa-
tion. As shown in Table 3, diseased subjects were obese,
with lower HDL cholesterol, elevated triglyceride levels,
uncontrolled diabetes, elevated inflammation (CRP),
and evidence of chronic kidney disease as revealed by
the elevated plasma creatinine.
Table 3 Demographic and biochemical characteristics of
study participants
Control (n = 10) Disease (n = 10) p value
Age (yrs) 58.4 (6.1) 62.2 (7.5) 0.233
Sex ( M:F) 4:6 5:5 0.99
BMI (kg/ m2) 24.3 (4.5) 37.8 (7.7) 0.001
Systolic BP (mm Hg) 122.4 (9.4) 131.4 (17.4) 0.173
Diastolic BP (mmHg) 74.8 (5.7) 70.7 (9.8) 0.275
LDL (mg/dL) 138.5 (35) 114.1 (42.2) 0.178
HDL (mg/dL) 58.7 (9.5) 36.1 (7.46) <0.001
CRP (mg/dL) 2.6 (2.27) 13.3 (11) 0.014
Triglycerides ( mg/dL) 111.1 (55) 309.2 (205) 0.014
Creatinine (mg/dL) 0.7 (0.15) 1.65 (0.93) 0.011
Glycated Hemoglobin % 5.4 (0.38) 9.2 (2.71) 0.002
Urine Microalbumin
(mcg/mg creatinine)
8.4 (6.7) 1667.5 (2596) 0.114
The samples were pooled from the control and disease groups. Values are
means (SD).
Table 4 Concentrations of Plasma and HDL proteins from
the pooled sample of the diseased subject (mg/mL)
Protein Plasma HDL 2X2 HDL
10X10
Apolipoprotein A-I (Apo A-I) 0.36 0.259 0.178
Alpha-1-Antitrypsin (AAT) 1.5 0.0688 0.00736
Immunoglobulin A (IgA) 2.5 0.00422 0.00054
Immunoglobulin M (IGM) 2.1 0.00275 0.00117
Complement C3 (C3) 1.5 0.00211 0.000792
Fibrinogen 4.7 0.00209 0.00118
Haptoglobin 2.3 0.00191 0.000438
Alpha-2-Macroglobulin 1.9 0.000857 0.00104
Apolipoprotein (a) (Lp (a)) 0.684 0.108 0.081
Fetuin-A 0.2 0.068 0.015
Complement Factor H 0.1 0.057 0.0036
Apolipoprotein D (Apo D) 0.05 0.041 0.018
Apolipoprotein C-III (Apo C-III) 0.07 0.039 0.028
Apolipoprotein B (Apo B) 1.0 0.028 0.01
Apolipoprotein H (Apo H) 0.246 0.016 0.00091
Vitronectin 0.26 0.013 0.0018
Apolipoprotein E (Apo E) 0.04 0.0074 0.0042
Clusterin (CLU) 0.37 0.0042 0.0011
Thyroxine-Binding Globulin (TBG) 0.044 0.0025 0.00033
Beta-2-Microglobulin 0.0041 0.00094 0.00033
Vitamin K-Dependent Protein S 0.05 0.00027 0.000074
Serum Amyloid P-Component 0.017 0.00015 0.000051
C-Reactive Protein (CRP) 0.015 0.00013 0.000023
CD5 (CD5L) 0.00053 0.000106 0.0000096
Vascular Cell Adhesion Molecule-1
(VCAM-1)
0.000761 0.000039 0.000011
Myoglobin 0.00013 0.000031 0.000016
Tissue Inhibitor of Metalloproteinases
1 (TIMP-1)
0.000104 0.0000097 0.0000012
Thrombospondin-1 0.00482 0.000008 0.0000036
Plasminogen Activator Inhibitor
1 (PAI-1)
0.000072 0.000004 0.0000005
Tumor Necrosis Factor Receptor
2 (TNFR2)
0.000014 0.0000017 0.0000001
T-Cell-Specific Protein RANTES
(RANTES)
0.0000097 0.0000015 0.0000004
EN-RAGE 0.000067 0.0000001 < LOW >
Myeloperoxidase (MPO) 0.00183 < LOW > 0.000019
Sex Hormone-Binding Globulin
(SHBG)
0.0016195 0.0000218 0.0000006
HDL 2.2 and 10.10 refer to two sequential ultra-centrifugations 2 or 10 hours
each. Samples were diluted 12 times and were run once at each dilution. The
reported concentrations were in the linear range of the assay (Additional file 1:
Table S1). The strength of this technique is in the ability to measure these HDL
proteins across a wide concentration range.
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One challenge in HDL proteomics is differentiating
whether proteins are actually present within HDL or are
predominately carried within plasma and have become
loosely associated with HDL before or during the isola-
tion procedure. We initially isolated HDL using a two
sequential spins (2 hrs × 2) and we are able to detect
several low abundance proteins commonly associated
with atherogenesis and inflammation using MAP (Table 1)
of participants with both diabetes and CVD. To confirm
whether these proteins are part of the HDL fraction or
loosely attached plasma proteins, a longer centrifugation
process was employed to isolate HDL (10 hrs × 2). Plasma
albumin levels were determined to be 45 mg/mL. After
the (2 hrs × 2) centrifugation, albumin levels within the
HDL fraction were 0.1 mg/mL. After prolonged sequential
centrifugation step (10 hrs × 2), albumin levels were
below the detection limits of this assay. Proteins detect-
able on HDL (by both centrifugation techniques) assessed
by MAP, along with plasma protein concentrations are
summarized in Table 4. We then correlated the concentra-
tions of these proteins between the different fractions. We
found no correlation between plasma and HDL proteins
identified in either the (2 hrs ×2) or (10 hrs ×2) HDL isola-
tion preparations. For example, Apo A-I concentrations of
0.36, 0.27, 0.18 mg/mL in plasma HDL (2 hrs × 2) and
HDL (10 hrs × 2), respectively shows clear retention on
HDL compared to fibrinogen with concentrations of
4.7, 0.0021, 0.0012 mg/mL. These findings confirm that
non-HDL proteins were efficiently depleted with the
longer centrifugation. In contrast, the HDL proteins iso-
lated with the (2 hrsx2) and (10 hrs × 10) methods were
highly correlated (Figure 1, r = 0.95, p < 0.001). As
Figure 1 Correlation of Plasma and HDL proteins using MAP. Plasma and HDL proteins were correlated using MAP. HDL (2×2) and HDL
(10×10) represent two different sequential centrifugation techniques that were 2 or 10 hours duration at the upper and lower densities of HDL.
As shown in the figure, there was no correlation between the concentrations of proteins between plasma and HDL. In contrast, the
concentration of proteins isolated using 2.2 and 10.10 were highly correlated (r = 0.95, P < 0.001).
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greater in the (2 hrs × 2) than the (10 hrs × 2) technique
(Table 3). The concentration of Apo A-I in plasma was
low in this sample pool from diseased participants com-
pared to healthy controls. Published Apo A -I levels are
in the 0.9-1.6 mg/mL range. This may suggest signifi-
cant HDL remodeling in advanced vascular disease.
Correlation of MAP and MRM
MRM’s performance for low abundance proteins is limited
without prior enrichment. Thus, MAP allows the mea-
surements of low abundance proteins on HDL. There
were 10 proteins common to both MAP and MRM, how-
ever, one protein (Apo E) was not detected in our samplesin 3 out of 4 samples by analyzed by MRM. We correlated
9 proteins measured by both approaches in 4 HDL sam-
ples. The results are summarized in Table 5. We did not
observe a good correlation for lipoprotein (a), Apo D and
Apo CIII between the two methods. Most of Lipoprotein
(a) is associated with LDL and present in low abundance
on HDL [16] reflecting a challenge for measuring this pro-
tein on HDL by MRM. Apo D on the other hand, has a
high degree of homology to retinol binding protein or
other members of the alpha 2 microglobulin protein
superfamily [17]. This might potentially pose a challenge
for the MAP technique. Apo CIII was another protein that
was measured by MAP and MRM with a weak correlation
between the two measurement platforms. It is not clear
Table 5 Correlation between MRM and MAP (Spearman)
Protein R P value
Apolipoprotein A-I (Apo A-I) 0.99 0.001
Fetuin-A 0.97 0.03
Apolipoprotein H (Apo H) 1 0.001
Clusterin (CLU) 1 0.008
Apo B 0.99 0.002
Lipoprotein (a) 0.8 0.2
Complement factor H 0.99 0.001
Apo D −0.2 0.5
Apo CIII - 0.06 0.9
The correlation between Myriad and MRM was based on the concentration of
common protein targets from the 4 HDL samples. There were 10 common
proteins between MAP and MRM. Apo E was not detectable in 3 out of the 4
samples by MRM and thus was not included in this list. For most of the
common proteins, the two assays were highly correlated.
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peptide used is not a good surrogate of Apo CIII levels.
Given that Apo CIII exists in multiple isoforms [18], both
assays could be measuring different forms.
HDL Proteome in diabetes and CVD
There is strong inverse association of HDL cholesterol
and cardiovascular disease (CVD). However, recent studies
suggested that niacin or CETP inhibition designed to raiseFigure 2 HDL protein ratio in disease vs healthy using MAP. Two poo
diabetes and CVD were submitted to proteins analysis by MAP. The figure
individuals. Several proteins implicated in atherogenesis (MPO, TNRF 2, IL1HDL-C content did not lead to improved CVD outcomes
[9-11]. This discrepancy highlights the need to revise our
view of HDL and its functions. One previous study dem-
onstrated that HDL acquires an inflammatory phenotype
in acute coronary syndrome [3]. Our results suggest that
examining HDL by MAP and MRM can reveal important
insights into its biology. One significant finding in our
study is the ability to detect for the first time important
proposed mediators of atherosclerosis (ENRAGE, MPO,
and PAI-1) on HDL using MAP. We also optimized an
MRM transition library for the high throughput monitor-
ing of HDL peptides. To investigate the HDL proteome in
CVD, HDL-containing samples from 10 non-diabetic par-
ticipants and HDL from subjects with both diabetes and
prior CVD events were pooled into a control and a DM/
CVD sample pool. 69 out of the 90 humanMAP proteins
showed acceptable recovery in response to multiple dilu-
tions (Additional file 1: Table S1) and were above the
lower limit of detection in both sample pools. Figure 2
represents the ratio of the 69 proteins on HDL between
disease and control participants. Our findings suggested
that several atherosclerosis-associated and inflammatory
proteins were increased on HDL of diseased individuals.
In addition, MPO, PAI-1, IL1beta, and ENRAGE were
only detected on HDL of diseased individuals. We ac-
knowledge that by pooling the samples, the clinical utilityled HDL samples of 10 non-diabetic participants and 10 subjects with
shows the ratio of HDL proteins in the diseased and the control
beta) were detected in the HDL of diseased individuals.
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and without disease is needed to fully characterize the
distribution of these low abundance proteins on HDL. Un-
like MAP, the sensitivity of MRM is limited without prior
sample enrichment. Hence, the accuracy of the assay is
compromised when sample concentrations fall below the
linear range of the assay as evidenced by the increased
coefficient of variation (CV) in several MRM proteins.
By MRM, we targeted transitions of 56 proteins. We
were able to detect 32 proteins of which 11 proteins had
CVs less than 20% on the replicate runs (Tables 1 and 2).
Clusterin is a high abundant protein that is associated
with HDL. We were able to quantitate clusterin accur-
ately in plasma (CV < 5% [6]); however we were not
able to reliably measure it in HDL as was previously
demonstrated [8] reflecting the challenges of using
MRMs for protein quantification when levels of a given
target falls out of the dynamic range in diseased states.
Comparing HDL proteins in the CVD versus control
pool by MRM revealed the depletion of several lipid
metabolism proteins such as Apo CI, CII and PON-1
in CVD. In contrast, the concentrations of several
acute phase proteins such as clusterin, Complement C9,
alpha-1-antitrypsin were increased in CVD (Figure 3).Figure 3 HDL protein ratio in disease vs healthy using MRM. Two poo
diabetes and CVD were submitted to proteins analysis by MRM. The figure
individuals using MRM. Proteins involved in lipid metabolism were decreas
of participants with CVD.These findings would facilitate conducting larger studies
using the presented approach to examine the effect of
inflammation and atherosclerosis associated proteins on
HDL composition and function in individuals with dia-
betes and CVD.Challenges of measuring lipid associated proteins
Measurement of lipid associated proteins has been suc-
cessful using immunoassays based on nephelometry and
mass spectrometry [1,4,8]. Nephelometry is not widely
available and not amenable to multiplexing. Conventional
mass spectrometry techniques using spectral counting or
extracted ion chromatograms can be lengthy and challen-
ging in large sample sizes. Here, we present two alterna-
tives (MAP and MRM) that are amenable to multiplexing,
and are high throughput. MAP is limited by the availabil-
ity and quality of pre-exiting antibody panels. MRM, on
the other hand, can lose sensitivity at the lower end of
abundance. Although the performance of MRM in lower
abundance HDL proteins was inferior to immune based
assays, the performance of MRM is likely to improve with
the development of more sensitive mass spectrometry
analyzers and better sample fractionation methods.led HDL samples of 10 non-diabetic participants and 10 subjects with
shows the ratio of HDL proteins in the diseased and the control
ed whereas proteins involved in inflammation were increased on HDL
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There are several limitations of this study. First, the
present study was done with two pools of clinical sam-
ples. As such, the present work describes an alternative
analytical tool for the measurement of HDL proteins.
Application of these assays to larger clinical data sets is
feasible and will allow determination of their clinical
utility. Second, the digestion efficiency of each protein
monitored by MRM was not assessed. However, we have
previously shown [19] that if the digestion procedure is
consistent and reproducible, then the ability to compare
quantitative values between samples is maintained. Thus,
the results presented are better described as “relative
accurate abundances”. Despite this limitation, several
peptides quantitated by MRM were correlated with
measurement using MAP (Table 5) affirming our claim
that the MRM assay can provide absolute quantitation.
A third limitation of this study is that we did not use an
independent method of HDL isolation (such as reciprocal
co-immunoprecipitation of a given protein with Apo A-I,
or gel filtration as suggested by Davidson et al. [20]) to
validate that presence of these low abundance proteins
on HDL. However, HDL isolated by a longer centrifuga-
tion step had successfully depleted albumin with several
of the low abundance proteins still detectable on HDL.
In addition, the proteins on HDL and the corresponding
plasma concentrations did not correlate, whereas the
two HDL fractions were highly correlated. This finding
suggests that these low abundance proteins were not
contaminant plasma proteins. Our findings however,
need to be replicated in a larger study group.Conclusions
This study suggests the feasibility of measuring HDL
proteins using MRM and MAP. The application of MAP
and MRM to the HDL proteome offers the potential to
improve our understanding of HDL functions and help
direct interventions aimed at remodeling the HDL pheno-
type in diabetes and CVD.Additional file
Additional file 1: lists (1) details of MRM method summary.
(2) Table S1. showing the HDL protein concentrations after 12 dilutions for
determination of lower limit of detection (linearity analysis) (3) Table S2.
listing all the transitions used to screen for HDL proteins (4) Figure S1.
showing representative chromatograms from the 4 replicate runs.
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